EGFR and phospho-EGFR expression in colorectal cancer patients and impact on survival

• DOI: 10.1200/jco.2005.23.16_suppl.3690
• Publication Date: 2017-02-23T13:55:09Z
• Authors: J.-P. Spano; A. T. Hbibi; C. Lagorce; G. Desguetz; R. Benamouzig; O. Rixe; J.-F. Morere; A. Martin; R. Fagard
• Keywords: Tissue microarray; EGFR Inhibitors

3690 Background: Epidermal growth factor receptor (EGFR) is overexpressed in many types of cancers, especially colorectal cancer (CRC). Blocking EGFR activation represents an innovative strategy patient care but additional efforts are needed to establish better predictors the efficacy inhibitors. In present study, we evaluated and activated EGFR, such as phospho-EGFR, by immunohistochemistry (IHC) tissue microarrays (TMA) CRC patients analyzed their relationships with various clinical histological parameters survival. Methods: Tumor blocks were obtained from arranged a microarray (Beecher Instruments). Four biopsies, 0.6 mm diameter, each donor block. IHC was performed using anti-EGFR anti-bodies (Zymed, USA) anti-phospho-EGFR (tyr 845, tyr 992, 1045, 1068). A composite score used define low or high phospho-EGFR levels expression (0–9). Univariate tests multivariate Cox proportional hazards model applied for data analysis. Results: detected 78% 126 patients. Phospho-EGFR 845 found 100% cases, inferior 6 40% cases superior 60% cases. Phospho-tyr 1068 respectively 23%, 0%, 0% The phosphor-EGFR mainly located nucleus. No relationship between other clinicopathological variables either overall Conclusions: expressed population some 992. Thus linking molecular diagnostics identify where target would be necessary translate these findings into targeted therapeutic approaches.These could therefore offer opportunity test inhibitors setting. Other biomarkers downstream signaling pathway still our will presented. significant financial disclose.